|
|
Article: Canadian discovery for the treatment of Chronic Hepatitis B is approved in Canada... offers real hope to thousands of infected Canadians.
- Article from:
- PR Newswire
- Article date:
- November 30, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Hundreds of millions of people infected worldwide
LAVAL, QC and MISSISSAUGA, ON, Nov. 30 /CNW-PRN/ - Glaxo Wellcome Inc. and BioChem Pharma Inc. announced today that Heptovir(TM) (lamivudine), the first oral anti-viral medication for the treatment of chronic hepatitis B, was approved by the Therapeutic Products Program of Health Canada. Experts believe that Heptovir is set to revolutionize the treatment of hepatitis B for millions of people infected with the virus around the world.
``Heptovir is a very significant development in the management of hepatitis B infection,'' said Dr. Michael Levy, Senior Vice President, Research and Development and Chief ...